Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics
Clinical trials sponsored by Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics, explained in plain language.
-
New daily pill shows promise for weight loss in obesity trial
Disease control OngoingThis study tests a new daily pill, aleniglipron, to help people with obesity or overweight lose weight. About 220 adults will take either the drug or a placebo for 36 weeks. The goal is to see how much weight they lose and if the drug is safe.
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New obesity drug shows promise in phase 2 fat-loss trial
Disease control OngoingThis study tests a new medication called aleniglipron (GSBR-1290) to see if it helps people with obesity lose body fat. About 71 adults with a BMI of 30 or higher will receive either the drug or a placebo for 40 weeks. The main goal is to measure changes in total body fat using a…
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New pill shows promise for diabetes and weight loss in early trial
Disease control OngoingThis study tests a new medication called aleniglipron in adults with type 2 diabetes who are also overweight or have obesity. The main goal is to check if the drug is safe and tolerable at different doses. Researchers will also measure changes in body weight and blood sugar level…
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:04 UTC